MAPT and Alzheimer disease: Note that these findings differ from those of Ewers et al. [43], where both among familial and sporadic AD, measures of SyS were found to attenuate the effect of pathology (estimated by years to symptom onset in the former and measured by tau-PET in the second) on cognitive function.